-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article was originally written by Translational Medicine.
Please indicate the source Author: Jasmine Introduction: In 1873, the Russian doctor J.
von Rusitzky created "multiple myeloma" after discovering eight different types of myeloma in a patient.
word
.
Nearly 150 years later, using advanced cell sequencing and state-of-the-art imaging, researchers at Roswell Park Comprehensive Cancer Center have provided a molecular and biological explanation for the discovery, finding that different myeloma may be present in a single patient Cloning and linking distinct genetic changes in myeloma cells to the development of myeloma bone disease
.
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow that makes antibodies to fight infection
.
In myeloma patients, however, plasma cells proliferate too quickly, crowding out healthy cells and causing painful areas of bone damage, known as osteolytic lesions
.
However, why do cancer cells in people with multiple myeloma cause debilitating bone disease in some parts of the body while others are not? This has been an unknown for many years
.
The research team consisted of multidisciplinary experts, unprecedented in a prospective clinical trial of this type, including Jens Hillengass, MD, Chief of the Division of Myeloma, and Philip, Director Emeritus of Transplantation and Cell Therapy at Roswell Park Comprehensive Cancer Center Dr.
McCarthy
.
Using a combination of single-cell RNA-sequencing and image-guided biopsy of myeloma bone disease lesions, researchers have identified substantial spatial heterogeneity in patients with relapsed/refractory, newly diagnosed multiple myeloma
.
The study, published February 10 in Nature Communications, is titled: "Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
" The study links the accumulation of malignant, pathogenic plasma cells to the effects of myeloma bone disease.
The development link provides answers to long-standing questions in the field of multiple myeloma research that may change how the disease is diagnosed and treated
.
https://doi.
org/10.
1038/s41467-022-28266-z "A multidisciplinary approach reveals important information about spatial and temporal heterogeneity in multiple myeloma
.
We found that both in different bone marrow regions , or at different times, myeloma cells differed in individual cells from individual patients,
"
noted Dr.
Hillengass, who is also the study's corresponding author
.
To further confirm the diagnosis of multiple myeloma, cancer specialists usually take a bone marrow biopsy from the iliac crest (hip bone) without the guidance of imaging techniques
.
In this prospective clinical trial, experts at Roswell Park Comprehensive Cancer Center not only biopsied the iliac crest of 10 patients with symptomatic multiple myeloma using state-of-the-art whole-body imaging technology (PET-CT) , myeloma bone lesions were also identified and biopsied (7 newly diagnosed cases, 3 relapsed/refractory cases)
.
Next, Comprehensive Cancer Center researchers from the departments of Medicine, Immunology, Diagnostic Radiology, Biostatistics, Bioinformatics, Flow and Image Cytometry, Clinical Cytogenetics, and Pathology and Laboratory Medicine joined Dana — Scientists at the Farber Cancer Institute collaborated to analyze hundreds of thousands of myeloma cells obtained during image-guided biopsies using single-cell RNA sequencing
.
The analysis showed that myeloma cells in different parts of the same patient were genetically distinct, especially in those with relapsed disease
.
The researchers identified a subpopulation of malignant myeloma cells that overexpressed genes associated with proliferation and oxidative phosphorylation, two cancer hallmarks associated with poorer prognosis
.
Obtaining Live Plasma Cells from Image-Guided Biopsies of Osteolytic Lesions and Bone Marrow When the team repeated the analysis of individual malignant plasma cells after patients had completed myeloma treatment, they found that residual malignant plasma cells after treatment emerged that may be associated with resistance therapeutically relevant genetic changes, suggesting that single-cell sequencing can be used not only to identify and characterize residual disease, but also to determine what strategies should be used in the future to make treatments work for patients
.
In addition to previously identified genes associated with myeloma, the researchers identified a new gene, LAMP5, that is overexpressed in bone lesions and is likely involved in disease progression
.
The authors note that because harvesting myeloma cells from the iliac crest alone does not provide a complete picture of the disease, obtaining additional information from imaging to identify treatment-resistant clones may become standard practice, especially when designing targeted personalization during treatment
.
"Our work underscores the importance of whole-body imaging in the diagnosis and treatment of myeloma because of strong evidence that distinct clones of myeloma exist in individual patients
.
If we want to cure myeloma, we need to Whole-body imaging was added to follow-up,
"
said study lead author Maximillian Merz, MD, who led the study while on the faculty at Roswell Park Comprehensive Cancer Center
.
The team's findings enhance current understanding of multiple myeloma and have implications for the treatment and monitoring of both newly diagnosed and relapsed patients
.
They stress that it will be possible to personalize treatment based on the different genetic makeup of each patient's myeloma, both at initial diagnosis and later in therapy
.
Reference: https://medicalxpress.
com/news/2022-02-sequencing-mystery-multiple-myeloma.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Events The First Yangtze River Delta Single Cell Omics Technology Application Forum [Webinar] Synthetic Biology Innovation and Development Popularity·Articles Stem Cell Research [Nature Sub-Journal] Using Stem Cells to Regenerate the Heart! Gene sequencing [Nature sub-journal] Analysis of 2658 complete DNA sequences - providing new clues for cancer mutations Cancer research [Science sub-journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Single-cell omics [guest announcement] The first Yangtze River Delta single-cell omics technology forum will be held in Shanghai in early March.
The second issue of precision medicine "Precision Medicine" is coming! What kind of sparks can CAR-T and MRD collide with? Big coffee gathered to explain to you! Detection and diagnosis [Nature sub-journal] Fudan University Wei Dacheng's team and academician Liu Yunqi have developed an ultra-high-sensitivity detection portable device that can produce results in 4 minutes! PCR detection or be replaced!
Please indicate the source Author: Jasmine Introduction: In 1873, the Russian doctor J.
von Rusitzky created "multiple myeloma" after discovering eight different types of myeloma in a patient.
word
.
Nearly 150 years later, using advanced cell sequencing and state-of-the-art imaging, researchers at Roswell Park Comprehensive Cancer Center have provided a molecular and biological explanation for the discovery, finding that different myeloma may be present in a single patient Cloning and linking distinct genetic changes in myeloma cells to the development of myeloma bone disease
.
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow that makes antibodies to fight infection
.
In myeloma patients, however, plasma cells proliferate too quickly, crowding out healthy cells and causing painful areas of bone damage, known as osteolytic lesions
.
However, why do cancer cells in people with multiple myeloma cause debilitating bone disease in some parts of the body while others are not? This has been an unknown for many years
.
The research team consisted of multidisciplinary experts, unprecedented in a prospective clinical trial of this type, including Jens Hillengass, MD, Chief of the Division of Myeloma, and Philip, Director Emeritus of Transplantation and Cell Therapy at Roswell Park Comprehensive Cancer Center Dr.
McCarthy
.
Using a combination of single-cell RNA-sequencing and image-guided biopsy of myeloma bone disease lesions, researchers have identified substantial spatial heterogeneity in patients with relapsed/refractory, newly diagnosed multiple myeloma
.
The study, published February 10 in Nature Communications, is titled: "Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
" The study links the accumulation of malignant, pathogenic plasma cells to the effects of myeloma bone disease.
The development link provides answers to long-standing questions in the field of multiple myeloma research that may change how the disease is diagnosed and treated
.
https://doi.
org/10.
1038/s41467-022-28266-z "A multidisciplinary approach reveals important information about spatial and temporal heterogeneity in multiple myeloma
.
We found that both in different bone marrow regions , or at different times, myeloma cells differed in individual cells from individual patients,
"
noted Dr.
Hillengass, who is also the study's corresponding author
.
To further confirm the diagnosis of multiple myeloma, cancer specialists usually take a bone marrow biopsy from the iliac crest (hip bone) without the guidance of imaging techniques
.
In this prospective clinical trial, experts at Roswell Park Comprehensive Cancer Center not only biopsied the iliac crest of 10 patients with symptomatic multiple myeloma using state-of-the-art whole-body imaging technology (PET-CT) , myeloma bone lesions were also identified and biopsied (7 newly diagnosed cases, 3 relapsed/refractory cases)
.
Next, Comprehensive Cancer Center researchers from the departments of Medicine, Immunology, Diagnostic Radiology, Biostatistics, Bioinformatics, Flow and Image Cytometry, Clinical Cytogenetics, and Pathology and Laboratory Medicine joined Dana — Scientists at the Farber Cancer Institute collaborated to analyze hundreds of thousands of myeloma cells obtained during image-guided biopsies using single-cell RNA sequencing
.
The analysis showed that myeloma cells in different parts of the same patient were genetically distinct, especially in those with relapsed disease
.
The researchers identified a subpopulation of malignant myeloma cells that overexpressed genes associated with proliferation and oxidative phosphorylation, two cancer hallmarks associated with poorer prognosis
.
Obtaining Live Plasma Cells from Image-Guided Biopsies of Osteolytic Lesions and Bone Marrow When the team repeated the analysis of individual malignant plasma cells after patients had completed myeloma treatment, they found that residual malignant plasma cells after treatment emerged that may be associated with resistance therapeutically relevant genetic changes, suggesting that single-cell sequencing can be used not only to identify and characterize residual disease, but also to determine what strategies should be used in the future to make treatments work for patients
.
In addition to previously identified genes associated with myeloma, the researchers identified a new gene, LAMP5, that is overexpressed in bone lesions and is likely involved in disease progression
.
The authors note that because harvesting myeloma cells from the iliac crest alone does not provide a complete picture of the disease, obtaining additional information from imaging to identify treatment-resistant clones may become standard practice, especially when designing targeted personalization during treatment
.
"Our work underscores the importance of whole-body imaging in the diagnosis and treatment of myeloma because of strong evidence that distinct clones of myeloma exist in individual patients
.
If we want to cure myeloma, we need to Whole-body imaging was added to follow-up,
"
said study lead author Maximillian Merz, MD, who led the study while on the faculty at Roswell Park Comprehensive Cancer Center
.
The team's findings enhance current understanding of multiple myeloma and have implications for the treatment and monitoring of both newly diagnosed and relapsed patients
.
They stress that it will be possible to personalize treatment based on the different genetic makeup of each patient's myeloma, both at initial diagnosis and later in therapy
.
Reference: https://medicalxpress.
com/news/2022-02-sequencing-mystery-multiple-myeloma.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Events The First Yangtze River Delta Single Cell Omics Technology Application Forum [Webinar] Synthetic Biology Innovation and Development Popularity·Articles Stem Cell Research [Nature Sub-Journal] Using Stem Cells to Regenerate the Heart! Gene sequencing [Nature sub-journal] Analysis of 2658 complete DNA sequences - providing new clues for cancer mutations Cancer research [Science sub-journal] Will "lactic acid" help cancer cells? Studies have found that specific enzymes can fight it! Single-cell omics [guest announcement] The first Yangtze River Delta single-cell omics technology forum will be held in Shanghai in early March.
The second issue of precision medicine "Precision Medicine" is coming! What kind of sparks can CAR-T and MRD collide with? Big coffee gathered to explain to you! Detection and diagnosis [Nature sub-journal] Fudan University Wei Dacheng's team and academician Liu Yunqi have developed an ultra-high-sensitivity detection portable device that can produce results in 4 minutes! PCR detection or be replaced!
